Philippe Moreau, MD, on the Implications of Daratumumab Maintenance for Newly Diagnosed Multiple Myeloma
Moreau discussed the implications of the second part of the CASSIOPEIA trial at the 2021 ASCO Annual Meeting.
CancerNetwork spoke with Philippe Moreau, MD, of the University Hospital of Nantes, at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, regarding implications from part 2 of the phase 3 CASSIOPEIA trial (NCT02541383), which investigated daratumumab (Darzalex) maintenance following bortezomib, thalidomide, and dexamethasone (VTd) for patients with newly diagnosed multiple myeloma.
Transcription:
The main takeaway is that daratumumab maintenance is able to improve outcomes following stem cell transplantation, [although] this is restricted to patients who are not exposed as part of frontline treatment with a quadruplet [regimen] including daratumumab. We definitely need a longer follow-up to look at progression-free survival 2 [PFS2] and overall survival. When we evaluated PFS2, we also showed that there is a clear separation of the curves that is now occurring with a follow-up of 3 years; we definitely need a longer follow-up. The best PFS2 curve is the one for patients who received daratumumab up front and daratumumab maintenance, as well.
Reference
Moreau P & Sonneveld P. Daratumumab (DARA) maintenance or observation (OBS) after treatment with bortezomib, thalidomide and dexamethasone (VTd) with or without DARA and autologous stem cell transplant (ASCT) in patients (pts) with newly diagnosed multiple myeloma (NDMM): CASSIOPEIA Part 2. J Clin Oncol. 2021;39(suppl 15):8004. doi:10.1200/JCO.2021.39.15_suppl.8004
![A third of patients had a response [to lifileucel], and of the patients who have a response, half of them were alive at the 4-year follow-up.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F6b7c9a3270c71a70749ba86000cfc78a29d74309-2988x1702.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "A third of patients had a response [to lifileucel], and of the patients who have a response, half of them were alive at the 4-year follow-up.")
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
![We must work on clinical predictors based on the disease phenotype, we must work on the physician’s attitude, and [we must work to] stimulate the correct and timely usage of ruxolitinib.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2Fd5a069c33bbfe917bc7c0b1bb13d76c0a815cc44-234x234.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "We must work on clinical predictors based on the disease phenotype, we must work on the physician’s attitude, and [we must work to] stimulate the correct and timely usage of ruxolitinib.")
